Fibroblast Growth Factor 21 in Lupus
Part of Immune system & allergy clinical trials.
This study is looking at the levels of a protein called fibroblast growth factor 21 (FGF21) in the blood of people with lupus (SLE). The goal is to find out if FGF21 is linked to disease activity or organ involvement, which could lead to better ways to monitor the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of systemic lupus erythematosus (SLE) using specific guidelines from 2019.
- You cannot have other rheumatic diseases or overlap syndromes (like having features of more than one autoimmune condition).
- You cannot have a current or past diagnosis of cancer (malignancy).
- You cannot have any liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying the role of a protein called FGF21 in women recently diagnosed with breast cancer. It aims to understand how FGF21 relates to breast cancer, which may help in future treatment decisions.
This study looks at how lupus kidney disease activity relates to bone mineral density. It may help understand if bone loss is linked to kidney inflammation in lupus.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
This study looks at a blood hormone called FGF23 and whether it is linked to heart (cardiovascular) problems in people with anemia. It also compares people with anemia who do and do not have chronic kidney disease, which may help researchers understand risk and targets.
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
This study looks at a simple blood test (called the Systemic Immune Inflammatory Index) to see if it can help doctors understand how active lupus is in your body. It includes people with lupus, especially those with kidney involvement, to find better ways to track the disease.
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.